Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 12a. Predictors of Disease Response or Survival—Patient Demographic Factors that Predict Response to Thalidomide: Summary

Prognostic Factor

Number of studies indicating significant correlation with tumor response/ total number of studies indicating factor

Number of studies indicating significant correlation with survival/ total number of studies indicating factor

Age

Correlation with response=2/3
(Barlogie, 2002109;Yakoub-Agha, 200260)

No correlation=1/3
(Shaughnessy, 2003133)

Correlation with survival=3/3
(Mileshkin, Biagi, et al., 200399; Shaughnessy, 2003133; Yakoub-Agha, 200260)

Gender

 

Correlation with survival=1/1
(Dimopoulos, 200494)

Performance status (PS measured on the ECOG PS scale)

Correlation with response=1/1
(Dimopoulos, 200170)

Correlation with survival=2/2
(Dimopoulos, 200170; Dimopoulos, 200494)

% of plasma cells in the BM

 

Correlation with survival=1/1
(Singhal, 199935)

Relapsed vs. refractory disease

Correlation with response=1/1
(Garcia-Sanz, 200495)

 

Time from diagnosis to onset of Thal

Correlation with response=1/1
(Yakoub-Agha, 200260)

 

Return to Document
Proceed to Table 12b

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care